Case Report Myeloid Neoplasms in the Guise of Nutritional Deficiency

Similar documents
Polycthemia Vera (Rubra)

Chronic Idiopathic Myelofibrosis (CIMF)

WHO Update to Myeloproliferative Neoplasms

Disclosure BCR/ABL1-Negative Classical Myeloproliferative Neoplasms

Opportunities for Optimal Testing in the Myeloproliferative Neoplasms. Curtis A. Hanson, MD

Disclosures. Myeloproliferative Neoplasms: A Case-Based Approach. Objectives. Myeloproliferative Neoplasms. Myeloproliferative Neoplasms

Myelodysplastic syndrome (MDS) & Myeloproliferative neoplasms

Heme 9 Myeloid neoplasms

Myeloproliferative Disorders in the Elderly: Clinical Presentation and Role of Bone Marrow Examination

Emerging diagnostic and risk stratification criteria

Year 2003 Paper two: Questions supplied by Tricia

Latest updates in Myeloproliferative Neoplasms. Elizabeth Hexner, MD, MSTR

MYELOPROLIFARATIVE NEOPLASMS. Dr. Hasan Fahmawi, MRCP(UK), FRCP(Edin).

I. Definitions. V. Evaluation A. History B. Physical Exam C. Laboratory evaluation D. Bone marrow examination E. Specialty referrals

CASE 106. Pancytopenia in the setting of marrow hypoplasia, a PNH clone, and a DNMT3A mutation

Polycythemia Vera and other Myeloproliferative Neoplasms. A.Mousavi

Bone marrow histopathology in Ph - CMPDs. - the new WHO classification - Juergen Thiele Cologne, Germany

Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure

2013 AAIM Pathology Workshop

Polycythemia Vera and Essential Thombocythemia A Single Institution Experience

Myeloid neoplasms. Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories:

Myeloproliferative Disorders - D Savage - 9 Jan 2002

Myeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas. James J. Stark, MD, FACP

HAEMATOLOGICAL EVALUATION OF ANEMIA. Sitalakshmi S Professor and Head Department of Clinical Pathology St John s medical College, Bangalore

Hematopathology Case Study

Faculty of Medicine Dr. Tariq Aladily

FBC interpretation. Dr. Gergely Varga

COEXISTENCE OF β-thalassemia AND POLYCYTHEMIA VERA: A CHICKEN-AND-EGG DEBATE?

Myelodysplastic Syndromes Myeloproliferative Disorders

Pathology. #11 Acute Leukemias. Farah Banyhany. Dr. Sohaib Al- Khatib 23/2/16

Welcome to Master Class for Oncologists. Session 3: 9:15 AM - 10:00 AM

HENATOLYMPHOID SYSTEM THIRD YEAR MEDICAL STUDENTS- UNIVERSITY OF JORDAN AHMAD T. MANSOUR, MD. Part 4 MYELOID NEOPLASMS

CLINICAL CASE PRESENTATION

Evaluation of Anemia. Md. Shafiqul Bari Associate professor (Medicine) SOMC

74y old Female with chronic elevation of Platelet count. August 18, 2005 Faizi Ali, MD Hematopathology Fellow

20/20 PATHOLOGY REPORTS

MYELOPROLIFERATIVE NEOPLASMS

ORIGINAL ARTICLE CLINICO PATHOLOGICAL REVIEW OF MEGALOBLASTIC ANAEMIA IN CHILDREN- A 7 YEAR PAEDIATRIC HOSPITAL EXPERIENCE

Case Presentation No. 075

Acute haemolysis and appearance of PNH-like clones in patients with vitamin B12 deficiency and iron deficiency after iron dextran administration

The Internists Approach to Polycythemia and Implications of Uncontrolled Disease

Myelodysplastic Syndromes: Everyday Challenges and Pitfalls

Anemia 1: Fourth year Medical Students/ October/21/ 2015/ Abdallah Abbadi.MD.FRCP Professor

JMSCR Vol 05 Issue 11 Page November 2017

[COMPREHENSIVE GENETIC ASSAY PANEL ON

Taking The Fear Out of Abnormal CBC s Problems of Production, Destruction or loss

Approach to the abnormal CBC

Characterization of MPL-mutated myeloid neoplasms: a review of 224 MPL+ cases

Juvenile Myelomonocytic Leukemia (JMML)

Case Workshop of Society for Hematopathology and European Association for Haematopathology

MPDs. Myeloproliferative Disorders OBJECTIVES MYELOPROLIFERATIVE NEOPLASMS

Nutritional anaemia. Dr J Potgieter Dept of Haematology NHLS - TAD

Hematology Unit Lab 2 Review Material

2013 Pathology Student

Deconstructing the CBC

Integrated Diagnostic Approach to the Classification of Myeloid Neoplasms. Daniel A. Arber, MD Stanford University

CLINICAL POLICY DEPARTMENT: Medical Management DOCUMENT NAME: JakafiTM REFERENCE NUMBER: NH.PHAR.98

MPDs. Myeloproliferative Disorders OBJECTIVES MYELOPROLIFERATIVE NEOPLASMS

Hematology 101. Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD

Introduction and Approach to Anemia

HEAMATOLOGICAL INDICES AND BONE MARROW BIOPSY

MPN What's new in the morphological classification, grading of fibrosis and the impact of novel drugs

London Cancer. Myelofibrosis guidelines. August Review August Version v1.0. Page 1 of 12

Update on Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Kaaren Reichard Mayo Clinic Rochester

Disclosures for Ayalew Tefferi

Moath Darwish. Waseem Alhaj. Tareq Adely

Collect and label sample according to standard protocols. Gently invert tube 8-10 times immediately after draw. DO NOT SHAKE. Do not centrifuge.

Disorders of Blood Cells & Blood Coagulation

Anemia in the elderly. Nattiya Teawtrakul MD., PhD

2007 Workshop of Society for Hematopathology & European Association for Hematopathology Indianapolis, IN, USA Case # 228

Avoiding Early Cancer Claims. Presentation #4. Hank George, FALU

The Complete Blood Count

Microcytic Hypochromic Anemia An Approach to Diagnosis

ADx Bone Marrow Report. Patient Information Referring Physician Specimen Information

(anemia) ก hemoglobin concentration, hematocrit deviation 1 1 ก hemoglobin, hematocrit mean corpuscular volume (MCV) 2

Chronic Myeloproliferative Disorders

John L Frater, MD Jeffery M Klco, MD, PhD Department of Pathology and Immunology Washington University School of Medicine St Louis, Missouri

MECHANISMS OF HUMAN DISEASE: LABORATORY SESSIONS LYMPHOMA. April 16, 2008

Susan Stegman, MD Medical Director AXA Equitable Life May 3, 2016

Clinical Perspective The Hematologist s View

Evaluation of Bone Marrow Biopsies and Aspirates ANNA PORWIT DEPARTMENT OF PATHOLOGY, LUND UNIVERSITY

INTERELATIONSHIP BETWEEN IDA AND VITAMIN D DEFICIENCY IS NOW ESTABLISHED

Approach to the child with anemia. Nittaya Wisanuyothin,MD. Pediatrics Department, Maharat Nakhonratchasima Hospital

A rare thing may be just like any other but it is also paradoxically nothing like any of them.

Myeloproliferative Neoplasms and Treatment Overview

Case Presentation. Attilio Orazi, MD

New WHO Classification of Myeloproliferative Neoplasms

UNUSUAL PRESENTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS

Disclosures for Ayalew Tefferi

MDS/MPN MPN MDS. Discolosures. Advances in the Diagnosis of Myeloproliferative Neoplasms. Myeloproliferative neoplasms

Lymphoma Case Scenario 1

APPROACHING TO PANCYTOPENIA

Myeloproliferative Neoplasms

Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data

Peripheral Blood Smear: Diagnostic Clues and Algorithms

A. ILEA 1* A. M. VLADAREANU 2 E. NICULESCU-MIZIL 3

Approach to a pale child

Case Report Acquired Elliptocytosis as a Manifestation of Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia

ESM Table 2 Data extraction form and key data from included studies

Transcription:

Hindawi Publishing Corporation Case Reports in Hematology Volume 2012, Article ID 826939, 5 pages doi:10.1155/2012/826939 Case Report Myeloid Neoplasms in the Guise of Nutritional Deficiency Veda Parthasarathy Department of Pathology, ESI-PGIMSR, 10 Sri Devi Krupa, 1st Main, 1st Block, RT Nagar, Bangalore 560032, India Correspondence should be addressed to Veda Parthasarathy, vedalallu@yahoo.com Received 15 September 2012; Accepted 11 October 2012 Academic Editors: E. Arellano-Rodrigo, N. Hamerschlak, K. Nakase, and J. Várkonyi Copyright 2012 Veda Parthasarathy. This is an open access article distributed under the Creative Commons Attribution License, which permitsunrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The classic BCR-ABL-negative myeloproliferative neoplasms (MPNs) which include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) are among the most frequent hematologic neoplasms. Because of their relatively smooth clinical course, it is likely that many of these MPNs actually go undetected. Considering the high prevalence of iron, folic-acid, and vitamin B 12 deficiencies in developing countries, their coexistence with MPN can be expected frequently. In such situations where both disorders coexist, MPN is often overlooked. This causes considerable diagnostic delay. In this paper, two cases of PMF and one case of PV where the diagnosis of MPN was delayed for about 3 years are discussed. Presence of concomitant vitamin B 12, folate, and iron deficiencies perhaps camouflaged the underlying MPN. Bearing in mind the possibility of MPN, even in the setting of apparent nutritional deficiency and performing a bone marrow evaluation, is the crucial step in unveiling the hidden MPN. 1. Introduction Myeloproliferative neoplasms (MPNs) are among the most frequent hematologic neoplasms, usually affecting the middle aged and elderly [1]. Classic BCR-ABL-negative (Philadelphia negative) MPN is an operational subcategory [2, 3] which includes polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Because of their relatively smooth clinical course, it is likely that many classic BCR-ABL negative MPN cases actually go undetected. Deficiencies of iron, folic acid, and Vitamin B 12 are known to occur in association with BCR-ABLnegative MPNs [4 6]. These deficiencies may be coincident, secondary, or perhaps a manifestation of the underlying MPN. In developing countries where nutritional deficiencies are prevalent, their coexistence with MPN can be expected more often. In such situations where both disorders coexist, MPN often goes unnoticed. This paper illustrates three cases of BCR-ABL-negative MPN which went unnoticed for few years owing to concurrent nutritional deficiencies. 2. Case 1 A 24-year-old female was referred with six months history of weakness and anorexia. Her records revealed that she had received hematinics and red cell concentrates several times in the past two years. She had undergone upper GI endoscopy and colonoscopy which were unremarkable. She was moderately built, had mild icterus, and spleen was palpable 4 cms below left costal margin. Her blood counts: Hb 9.3 g/dl, hematocrit 33.1%, WBC 8.8 10 9 /L, platelets 682 10 9 /L, MCV 103.8 fl, MCH 29.2 pg, mean platelet volume (MPV) 12.2 fl, RBC 3.2 10 12 /L, and reticulocytes 4%. Serum total bilirubin was 3.2 mg/dl, largely unconjugated and liver enzymes within normal range. Serum vitamin B 12 was 107 pg/ml and LDH 4556 IU/L. Coombs direct and indirect, Hb Chromatography, and iron studies were unremarkable. JAK2 mutation was not detected. Peripheral smear demonstrated severe anisopoikilocytosis with oval macrocytes and hypersegmented neutrophils. Platelets were increased in number, exhibiting marked anisocytosis with many giant forms (Figure 1). Bone marrow (BM) evaluation showed atypical megakaryocytes (Figure 1) in a backdrop of megaloblastic erythroid hyperplasia. Reticulin fibrosis grade 4/4 with osteosclerosis and grossly distended marrow sinusoids were apparent. Marrow features were consistent with fibrotic stage of PMF. Karyotypic analysis revealed 46,X,t (X;16)(q28;q22)/46,XX. There was an abnormal clone with translocation of segment q22 of chromosome 16 to q28 region of X chromosome (Figure 1(c)). Intramuscular injections of vitamin B 12 largely

2 Case Reports in Hematology 1 2 3 4 5 16 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y X (c) Figure 1: blood smear illustrating tear drop poikilocytes and giant platelets. BM biopsy showing an atypical megakaryocyte. H&E 45x. (c) Karyotypic analysis showing an abnormal clone with 46,X,t(X;16)(q28;q22). alleviated her symptoms. Hb improved to 12.1 g/dl and bilirubin values returned to normal. She was followed for four months through which her condition remained steady. 3. Case 2 A 53-year-old male was referred for persistent anemia during the past three years. Physical examination was unremarkable except for glossitis. Abdominal scan was normal. His initial investigations revealed Hb 5.8 g/dl, Hct 18.2%, MCV 95 fl, RBC 1.8 10 9 /L, reticulocytes 1.2%, WBC 36 10 9 /L with absolute neutrophil count 17.6 10 9 /L, platelets 76 10 9 /L. His serum folate was 2.1 ng/ml, vitamin B 12 380 pg/ml, iron 14 µg/dl, ferritin 14.3 ng/ml, transferrin saturation 10%, uric acid 9.2 mg/dl, and LDH 356 IU/L. Blood smear showed moderate anisopoikilocytosis, tear drop cells, neutrophil leukocytosis, and thrombocytopenia (Figure 2). There was no history of prior gastrointestinal surgery. Cause of anemia was initially attributed to the combined deficiencies of iron and folic acid. A month following red cell transfusions and treatment of the deficiencies, blood counts were as follows: Hb 10.5 g/dl, WBC 37.5 10 9 /L, platelets 75 10 9 /L, and reticulocytes 4.8%. BM biopsy revealed mostly hypercellular areas with increased M : E ratio. Megakaryocytes were increased in number, exhibiting highly pleomorphic nuclei and bizarre forms. Many nuclei had cloudy, balloon-like appearance. Reticulin fibrosis of grade 2/4 along with few distended marrow sinusoids was evident (Figures 2, 2(c), and 2(d)). These features characterized the cellular phase of PMF, presenting with combined deficiencies of iron and folic acid.

Case Reports in Hematology 3 (c) (d) Figure 2: Blood smear displaying anisocytosis and tear drop red cells. BM biopsy showing hypercellular areas and distended marrow sinusoids. Megakaryocytes appear prominent even at low magnification. H&E 4x scanner. (c) BM biopsy illustrating increased number of atypical megakaryocytes against a hypercellular background. The cloudy nature of megakaryocyte nuclei is evident. H&E 45x. (d) grade 2/4 reticulin fibrosis highlighted by silver staining. JAK2 mutation was negative and karyotype was normal. This case was referred to oncology for further management of MPN. 4. Case 3 A 60-year-old male came with complaints of dizziness and tingling sensation in his fingers since three years, which had worsened during the past 6 months. He had suffered a cerebrovascular accident before one year. Although his earlier Hb values varied between 16.2 to 17.3 g/dl, a diagnosis of PV was not cited in his medical records. Spleen was palpable six centimeters below the left costal margin. His blood counts were as follows: Hb 16.3 g/dl, Hct 53.4%, MCV 68.5 fl, MCH 20.7 pg, RBC 8.34 10 9 /L, reticulocytes 1.1%, WBC 14.2 10 9 /L with 75% neutrophils, platelets 581 10 9 /L. Peripheral smear showed microcytic, hypochromic red cells with neutrophilia and thrombocytosis (Figure 3). Serum ferritin was 12.4 ng/ml, iron 22 µg/dl, transferrin saturation 5.2% suggesting iron deficiency. Vitamin B 12 was 1447 pg/ml, LDH was 332 IU/L, and Hb chromatography confirmed a normal adult pattern. Serum erythropoietin level was within normal (45 U/L). JAK2 V617F was positive by PCR. BM was significantly hypercellular, with obliteration of fat spaces (Figure 3) and trilineage hyperplasia. There was no evidence of reticulin or collagen fibrosis. These features confirmed the diagnosis of PV, manifesting with secondary iron deficiency. 5. Discussion Three cases of Philadelphia-negative MPN, manifesting as longstanding nutritional deficiencies, are presented. All three

4 Case Reports in Hematology Figure 3: blood smear displaying hypochromic red cells and increased neutrophils. A nucleated red cell is also seen. Hypercellular marrow with obliteration of fat spaces. H&E 45x. patients were moderately built and nourished, with no history of prior gastrointestinal surgery. Case 1 illustrates PMF presenting as recurrent nutritional deficiency anemia. As nutritional deficiency is widely prevalent in India, further investigations to unveil the cause of anemia were not pursued for long. Her fundamental problem was overlooked for more than two years. This case also illustrates the importance of considering PMF in young patients. Unconjugated hyperbilirubinemia was attributed to ineffective hematopoiesis consequent to vitamin B 12 deficiency. Translocations involving X chromosome have previously been reported in ET, PV, and unclassifiable MPN [7 9]. Case 2 illustrates PMF presenting as longstanding anemia associated with combined nutritional deficiencies. There was no organomegaly, and JAK2 mutation was not detected. Inadequate response to treatment, neutrophil leukocytosis, numerous tear drop poikilocytes, and elevated uric acid raised a suspicion of PMF. Case 3 signifies PV presenting with normal Hct and normal erythropoietin levels. Although PV commonly presents with elevated Hct, this concept is so ingrained that the possibility of PV is not thought of unless Hct is obviously high. Occurrence of iron deficiency at presentation can lower the Hb to near normal levels, thereby masking PV. In such situations, marked erythrocytosis is an important hint signifying the likelihood of PV. Appropriate evaluation of red cell parameters can therefore assist in recognizing PV presenting with near normal Hb. Deficiencies of iron, folic acid, and vitamin B 12,alone or in combination, have been reported in association with MPN [4 6]. In identifying subtle deficiency of vitamin B 12 and folate, homocysteine and methyl malnoic acid (MMA) are proven to be more sensitive than serum cobalamin and folate. On the basis of measuring these metabolites before and after supplementation trials, Faurschou et al. [10] found a high incidence of both vitamin B 12 and folate deficiency in myeloproliferative disorders. In patients with myeloproliferative disorders, normal to high serum vitamin B 12 concentrations have often been reported [11]. Hypervitaminemia B 12 can sometimes paradoxically be accompanied by signs of deficiency reflecting a functional deficit related to defects in tissue uptake and action of vitamin B 12. In a cross sectional observatory study of 33 patients with myeloproliferative neoplasms, Gauchan et al. [12] have reported normal to elevated serum vitamin B 12 levels in all patients. However, 9 patients (27.3%) also exhibited elevated serum MMA, suggesting an occult cobalamin deficiency. In these patients, elevated levels of serum vitamin B 12 actually masked the true deficiency. Deficiencies of iron, vitamin B 12, and folic acid are widely prevalent affecting millions of people, particularly in developing countries [13]. Prevalence of vitamin B 12 and folic acid deficiencies is reported to be 33% and 6.8% in India [14], 51% and 17% in Zimbabwe [15], 56% and 8% in Pakistan respectively [16]. These deficiencies most frequently result from lack of proper nutrition. In developing countries where nutritional deficiencies are prevalent, their coexistence with MPN is even more likely. In such situations where both disorders coexist, MPN is frequently unnoticed. Diagnosis of MPN is an elaborate task, requiring BM evaluation and molecular markers. Nevertheless, diagnosis of nutritional deficiencies is generally straightforward. Besides, patients show noticeable clinical improvement after treatment of deficiency states [6]. So, further investigations are usually held back and diagnostic efforts come to a standstill. Unless the anemia is considerably longstanding, BM evaluation is not thought of. As a result, many cases of MPN go undetected for long. Lack of regular followup and inadequate documentation further delays their diagnosis. Nutritional deficiencies exhibit predominant anisopoikilocytosis, thereby masking the characteristic features of MPN, especially PMF. Occurrence of basophilia, tear drop poikilocytes, nucleated red cells, early myeloid precursors, giant platelets, agranular platelets, and megakaryocyte

Case Reports in Hematology 5 fragments in the peripheral blood smear are important clues pointing towards a primary myeloid neoplasm [17]. BM histology remains the mainstay in diagnosis of MPN, particularly in JAK2-negative cases and in situations where molecular genetics are not readily accessible. Suspecting an underlying MPN even in the context of nutritional deficiency and performing a BM biopsy is the key step in identifying these hidden disorders. References [1] A. M. Vannucchi, P. Guglielmelli, and A. Tefferi, Advances in understanding and management of myeloproliferative neoplasms, Cancer Journal for Clinicians, vol.59,no.3,pp. 171 191, 2009. [2] A. Tefferi, Annual clinical updates in hematological malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management, American Journal of Hematology, vol. 86, no. 3, pp. 292 301, 2011. [3] B. L. Stein and M. R. Alison, Primary myelofibrosis and the myeloproliferative neoplasms: the role of individual variation, Journal of the American Medical Association, vol. 303, no. 24, pp. 2513 2518, 2010. [4] H.Hassoun,M.Pavlovsky,S.Mansoor,andT.Stopka, Diagnosis of polycythemia vera in an anemic patient, Southern Medical Journal, vol. 93, no. 7, pp. 710 712, 2000. [5] J. M. Forshaw, L. Harwood, and D. J. Weatherall, Folic-acid deficiency and megaloblastic erythropoiesis in myelofibrosis, British Medical Journal, vol. 1, no. 5384, pp. 671 672, 1964. [6] I. Chanarin, Folate deficiency in the myeloproliferative disorders, American Journal of Clinical Nutrition, vol. 23, no. 6, pp. 855 860, 1970. [7] L.R.Munro,D.A.J.Stevenson,andD.J.Culligan, Translocation (X;5)(q13;q33) in essential thrombocythemia, Cancer Genetics and Cytogenetics, vol. 114, no. 1, pp. 78 79, 1999. [8] K. N. Manola, C. Stavropoulou, V. N. Georgakakos et al., SwitchinX-inactivationinaJAK2 V617F-negative case of polycythemia vera with two acquired X-autosome translocations, Leukemia Research, vol. 31, no. 7, pp. 1009 1014, 2007. [9] J. O Reilly, J. Crawford, J. Uzaraga, and P. Cannell, Translocation (X;20) involving the inactive X chromosome in a patient with myeloproliferative disorder, Cancer Genetics and Cytogenetics, vol. 158, no. 1, pp. 81 83, 2005. [10] M. Faurschou, O. J. Nielsen, M. K. Jensen, and H. C. Hasselbalch, High prevalence of hyperhomocysteinemia due to marginal deficiency of cobalamin or folate in chronic myeloproliferative disorders, American Journal of Hematology, vol. 65, pp. 136 140, 2000. [11] K. Serraj, M. Mecili, I. Housni, and E. Andrès, Hypervitaminemia B12 (high level of cobalamin): physiopathology, role and interest in clinical practice, Presse Médicale, vol. 40, pp. 1120 1127, 2011. [12] D. Gauchan, N. Joshi, A. S. Gill et al., Does an elevated serum vitamin B(12) level mask actual vitamin B(12) deficiency in myeloproliferative disorders? Clinical Lymphoma Myeloma and Leukemia, vol. 12, no. 4, pp. 269 273, 2012. [13] M. Martin Bloem et al., IDA: prevention, assessment and control, in Report of a Joint WHO/UNICEF/UNU Consultation, World Health Organization, Geneva, Switzerland, 1998. [14] U. Khanduri, A. Sharma, and A. Joshi, Occult cobalamin and folate deficiency in Indians, National Medical Journal of India, vol. 18, pp. 182 183, 2005. [15] J. M. Mukibi, F. A. Makumbi, and C. Gwanzura, Megaloblastic anemia in Zimbabwe: spectrum of clinical and hematological manifestations, East African Medical Journal, vol. 9, pp. 83 87, 1992. [16] Modood-ul-Mannan, M. Anwar, M. Saleem, A. Wiqar, and M. Ahmad, A study of serum vitamin B12 and folate levels in patients of megaloblastic anaemia in northern Pakistan, Journal of the Pakistan Medical Association, vol. 45, no. 7, pp. 187 188, 1995. [17] B. J. Bain, D. M. Clark, and B. S. Wilkins, Myeloproliferative and Myelodysplastic/Myeloproliferative neoplasms and related conditions, in Bone Marrow Pathology, pp. 250 266, Blackwell Publishing, London, UK, 4th edition, 2010.